Compare SILC & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SILC | CNTN |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | Israel | United States |
| Employees | N/A | 12 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.8M | 185.3M |
| IPO Year | 2002 | 2022 |
| Metric | SILC | CNTN |
|---|---|---|
| Price | $41.34 | $3.11 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 180.2K | ★ 461.0K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $2.89 |
| 52 Week High | $52.58 | $5.27 |
| Indicator | SILC | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 42.96 |
| Support Level | $40.00 | $3.04 |
| Resistance Level | $50.75 | $3.82 |
| Average True Range (ATR) | 4.20 | 0.27 |
| MACD | -0.99 | -0.01 |
| Stochastic Oscillator | 5.15 | 10.39 |
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.